Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
42 shown of 9,269 total abstracts
  1. Abstract 14592026-04-05 · 15:15 CT · S406
    MONARCH-428: Verzenio (abemaciclib) 2L in HR+ breast cancer
    A. Spira, S. Peters, S. Antonia, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 12002026-04-01 · 15:00 CT · E450
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-743
    T. Mok, C. Robert, M. Reck · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 10852026-04-03 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-818 study)
    P. Schmid, T. Mok · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 17352026-04-05 · 19:00 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    J. Cortes, N. Rizvi, A. Spira · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 19422026-04-01 · 14:00 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    C. Saura, A. Spira, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 13382026-04-02 · 18:15 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-411
    L. Paz-Ares, E. Winer, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 11742026-04-04 · 20:15 CT · S406
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    R. Herbst, H. Borghaei, L. Paz-Ares, et al. · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 13052026-04-02 · 18:00 CT · S100A
    Quality of life outcomes with Trodelvy in patients with TNBC
    E. Winer, C. Robert, T. Mok · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 10522026-04-03 · 15:00 CT · Hall B1
    MONARCH-813: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    R. Herbst, C. Saura, P. Schmid, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 10842026-04-01 · 20:30 CT · E450
    Long-term follow-up of Keytruda 3L+ for TNBC: KEYNOTE-678
    M. Reck, F. Andre, M.C. Garassino, et al. · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 13662026-04-01 · 13:15 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    P. Schmid, M. Reck, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 11262026-04-05 · 19:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-935
    F. Andre, H. Rugo, T. Mok, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 10222026-04-02 · 14:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-614
    G. Curigliano, H. Rugo, S. Modi, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 14052026-04-02 · 21:15 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-670
    G. Curigliano, S. Peters, C. Saura · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 12942026-04-03 · 18:00 CT · S406
    OlympiA-555: Lynparza (olaparib) 1L in HR+ breast cancer
    L. Paz-Ares, T. Mok, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 16032026-04-03 · 16:45 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-753
    M. Reck, S. Peters · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 19412026-04-05 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-142
    M.C. Garassino, M. Reck, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 17122026-04-03 · 20:30 CT · Arie Crown Theater
    PALOMA-370: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    A. Spira, C. Robert, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 14792026-04-03 · 15:15 CT · Hall B1
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    C. Saura, M.C. Garassino, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 11672026-04-03 · 13:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-82
    H. Rugo, M.C. Garassino, J. Brahmer, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 15032026-04-01 · 20:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-315
    R. Herbst, F. Andre, H. Borghaei, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 10512026-04-04 · 16:00 CT · E450
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    S. Antonia, S. Modi · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 11172026-04-03 · 16:15 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-240 study)
    S. Peters, C. Saura, S. Modi · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 11172026-04-02 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-800
    G. Curigliano, R. Herbst, S. Tolaney · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 10402026-04-05 · 15:30 CT · E450
    MONALEESA-822: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    T. Mok, P. Schmid, H. Borghaei, et al. · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 19772026-04-02 · 20:00 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-731
    E. Winer, H. Rugo · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 11112026-04-05 · 14:00 CT · Hall B1
    MONALEESA-66: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    R. Herbst, H. Rugo, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 16002026-04-03 · 16:15 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-88
    G. Curigliano, N. Rizvi, S. Tolaney, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 16942026-04-03 · 20:30 CT · Hall B1
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-683
    S. Peters, A. Spira, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 14472026-04-04 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-663 study)
    H. Borghaei, S. Peters, M. Krop, et al. · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 18182026-04-05 · 19:00 CT · S100A
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-37
    J. Cortes, S. Peters, G. Curigliano · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 13962026-04-02 · 21:45 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-902 study)
    M. Reck, C. Saura · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 11282026-04-03 · 18:30 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-754
    L. Paz-Ares, M. Krop, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 16802026-04-05 · 18:15 CT · Hall B1
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    S. Modi, M.C. Garassino, A. Spira, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 15302026-04-04 · 13:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-775
    P. Schmid, S. Modi, G. Curigliano · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 12142026-04-03 · 19:45 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-787
    J. Brahmer, M. Krop · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 17552026-04-03 · 14:15 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-80 study)
    J. Cortes, C. Saura, S. Peters · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 12132026-04-02 · 20:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-728 study)
    L. Paz-Ares, F. Andre · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 14792026-04-04 · 15:00 CT · Hall B1
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-440
    M. Krop, J. Cortes · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 16892026-04-05 · 20:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-8
    S. Tolaney, S. Antonia, F. Andre, et al. · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 11432026-04-01 · 15:30 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-546
    S. Peters, M. Krop, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 10142026-04-04 · 21:00 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-16
    A. Spira, E. Winer, S. Modi · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.